SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Apricus Biosciences
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: hentied who wrote (1866)4/20/2016 12:02:11 PM
From: mokelumne river  Read Replies (1) of 2026
 
I am going to suggest that the asset that Denner wanted to control was Fispemifene, and thus his interest in Repros (Androxal). Seems that Denner (like Pascoe with us riding along) lost the bet on Fispemifine and Androxal.

So we (and Denner) are back down to the asset that Apricus was founded upon, Vitaros. At this point I would think that Denner would let things play out with Vitaros. To Pascoe's credit, he negotiated getting US rights back and may have a path through the FDA. I should note that Pascoe's only expert in dealing with the FDA is Troupin who is leaving at the end of May. That is a little concerning to me.

Back to your point Hentied, I would be more worried if Denner were an Icahn clone. I don't think that Denner has the same gut and strip mentality as his former mentor has. But we will see.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News